Yusuke Nakamura to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Yusuke Nakamura has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
1.917
-
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug; 49(2):471-8.
Score: 0.275
-
Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug; 104(8):1074-82.
Score: 0.224
-
Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level. Jpn J Clin Oncol. 2011 Aug; 41(8):1023-30.
Score: 0.195
-
Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol. 2010 Jul; 40(7):684-9.
Score: 0.180
-
[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital]. Gan To Kagaku Ryoho. 2009 Aug; 36(8):1287-91.
Score: 0.172
-
Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2007 Jan; 98(1):113-7.
Score: 0.144
-
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005 Apr 01; 11(7):2625-36.
Score: 0.127
-
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334.
Score: 0.088
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
Score: 0.072
-
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900.
Score: 0.069
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.068
-
Case of malignant melanoma that developed the ability to secrete granulocyte colony-stimulating factor. J Dermatol. 2016 May; 43(5):580-2.
Score: 0.067
-
A phase ?I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med. 2014 Apr 30; 12:108.
Score: 0.060
-
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
Score: 0.059
-
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009 Oct; 54(10):564-71.
Score: 0.043
-
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2268-70.
Score: 0.041
-
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy]. Gan To Kagaku Ryoho. 2006 Jul; 33(7):977-9.
Score: 0.035